Evidence map›Paper›PMID 27515775›Full record

ReviewJournal of hepatology2016

Sarcopenia from mechanism to diagnosis and treatment in liver disease.

Srinivasan Dasarathy, Manuela Merli

4 registry-linked trialsOpen access · greenAbstract readReview
In one paragraph

Review in Journal of hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 302 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
302citing papers in PubMed, 11 pooled it
30.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03285217 nacompletednot on this mapstarted 2017, after this paper: background citation

HMB for Denutrition in Patients With Cirrhosis (HEPATIC)

TypeinterventionalSponsorInstituto Aragones de Ciencias de la SaludRan2017 to 2019Enrolled43ConditionsSarcopenia, Cirrhosis, MalnutritionArmsEnsure Plus Advance, Ensure High Protein
NCT03633279 phase3active not recruitingnot on this mapstarted 2018, after this paper: background citation

Treatment of Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis- Child C: A Randomized Double Blind Control Trial

TypeinterventionalSponsorDayanand Medical College and HospitalRan2018 to 2025Enrolled96ConditionsLiver CirrhosisArmsBranched chain amino acid, Placebo
NCT05448222 unknown statusnot on this mapstarted 2022, after this paper: background citation

Effect of Sarcopenia on the Efficacy and Prognosis of HCC Treated With Systemic Therapies

TypeobservationalSponsorFirst Affiliated Hospital of Wenzhou Medical UniversityRan2022 to 2024Enrolled300ConditionsHepatocellular Carcinoma, SarcopeniaArmsDiagnostic Test: gait speed, ct scan, grip strength and chair stand test
NCT06531200 not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Building of Prognosis Model for Patients With Cirrhosis Based on Sarcopenia in Assessment With the Technology of Deep Learning

TypeobservationalSponsorPeking University People's HospitalRan2024 to 2025Enrolled1,000ConditionsCirrhosis, Liver, Sarcopenia
3 · Its place in the literature

Who cites it

302 citing papers in PubMed, 11 syntheses or guidelines pooled it, 587 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Guideline
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

242 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Srinivasan DasarathyDepartment of Gastroenterology, Hepatology and Pathobiology, Cleveland Clinic, United States. Electronic address: dasaras@ccf.org.
Manuela MerliGastroenterology, Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy.
Cleveland Clinic · USSapienza University of Rome · IT

Funding

Project Two - Exercise Training Decreases Alcohol Drinking by an FGF21-Dependent MechanismP50AA024333 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI LAURA E. NAGY · 2016 to 2026
$19.6M
Non Alcoholic Steatohepatitis Clinical Research NetworkU01DK061732 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI Srinivasan Dasarathy · 2002 to 2026
$12.2M
Novel Therapies for Alcoholic HepatitisU01AA021893 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI MCCLAIN, CRAIG J., MCCULLOUGH, ARTHUR JOSEPH · 2012 to 2017
$6.0M
Mechanisms of Malnutrition in Cirrhosis with Portosystemic ShuntingR01DK083414 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI DASARATHY, SRINIVASAN · 2011 to 2015
$1.8M
Alcohol induces muscle autophagy by a novel AMPK independent PI3K mediated mechanR21AA022742 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI DASARATHY, SRINIVASAN · 2014 to 2015
$410k
NIAAA NIH HHS P50 AA024333NIAAA NIH HHS R21 AA022742NIAAA NIH HHS U01 AA021893NIDDK NIH HHS R01 DK083414NIDDK NIH HHS U01 DK061732
6 · The paper itself

Abstract

Sarcopenia or loss of skeletal muscle mass is the major component of malnutrition and is a frequent complication in cirrhosis that adversely affects clinical outcomes. These include survival, quality of life, development of other complications and post liver transplantation survival. Radiological image analysis is currently utilized to diagnose sarcopenia in cirrhosis. Nutrient supplementation and physical activity are used to counter sarcopenia but have not been consistently effective because the underlying molecular and metabolic abnormalities persist or are not influenced by these treatments. Even though alterations in food intake, hypermetabolism, alterations in amino acid profiles, endotoxemia, accelerated starvation and decreased mobility may all contribute to sarcopenia in cirrhosis, hyperammonemia has recently gained attention as a possible mediator of the liver-muscle axis. Increased muscle ammonia causes: cataplerosis of α-ketoglutarate, increased transport of leucine in exchange for glutamine, impaired signaling by leucine, increased expression of myostatin (a transforming growth factor beta superfamily member) and an increased phosphorylation of eukaryotic initiation factor 2α. In addition, mitochondrial dysfunction, increased reactive oxygen species that decrease protein synthesis and increased autophagy mediated proteolysis, also play a role. These molecular and metabolic alterations may contribute to the anabolic resistance and inadequate response to nutrient supplementation in cirrhosis. Central and skeletal muscle fatigue contributes to impaired exercise capacity and responses. Use of proteins with low ammoniagenic potential, leucine enriched amino acid supplementation, long-term ammonia lowering strategies and a combination of resistance and endurance exercise to increase muscle mass and function may target the molecular abnormalities in the muscle. Strategies targeting endotoxemia and the gut microbiome need further evaluation.

Indexed as

SarcopeniaKetoglutaric AcidsLiver DiseasesMuscle, SkeletalQuality of LifeKetoglutaric AcidsClinical outcomesHyperammonemiaLeucinemTORC1MyostatinSarcopenia

Identifiers

PMID27515775
PMCPMC5116259
OpenAlexW2507464717

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.